Nefecon and Ambrisentan in IgA Nephropathy

Abroad (travel likely)RecruitingPHASE4

Conditions

IgA Nephropathy · Chronic Kidney Disease · Proteinuria

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

The First Hospital of Jilin University, Changchun, Jilin, China
Contact: Study coordinator (Weixia Sun, M.D.) · sunwx@jlu.edu.cn · 15804300380
Contact: Study coordinator (Yi Yang, M.M.) · 15048136878@163.com · 15048136878

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy

IgA Nephropathy

Abroad (travel likely)RecruitingPHASE4

Birmingham, United States · Glendale, United States

Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?

IgA Nephropathy · Renal Insufficiency, Chronic · IgA Vasculitis

Abroad (travel likely)RecruitingPHASE4

Nadiād, India · Mysuru, India

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN

Berger Disease · Bergers Disease · IgA Nephropathy

Abroad (travel likely)RecruitingPHASE3

Neptune City, United States · Cincinnati, United States

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

Primary IgA Nephropathy

Abroad (travel likely)RecruitingPHASE3

Alabaster, United States · Birmingham, United States